Lutsey PL, Norby FL, Ensrud KE, et al. - This comparative effectiveness cohort study was conducted to investigate the assumption that, among individuals with nonvalvular AF, the use of DOACs vs warfarin is correlated with a lower risk of incident fracture. The MarketScan administrative claims databases were applied to distinguish individuals with nonvalvular AF and who were prescribed oral anticoagulants between January 1, 2010, and September 30, 2015. A total of 167,275 individuals with AF were recruited in this study. Data were examined between February 27, 2019, and September 18, 2019. The use of DOACs—especially apixaban—compared with warfarin use was linked with lower fracture risk in this real-world population of 167,275 individuals with AF. These relationships were more noticeable among individuals with a diagnosis of osteoporosis. Given the potential adverse outcomes of warfarin on bone health, the results indicated that caution should be used when prescribing warfarin to individuals with AF at high risk of fracture.